# Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

> **NCT00247663** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Postmenopausal Women With Advanced Breast Cancer

## Interventions

- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00247663
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2005-12
- **Final completion:** —
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2012-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00247663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00247663, "Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00247663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*